Venetoclax plus navitoclax in R/R ALL and lymphoblastic lymphoma

Treating acute lymphoblastic leukaemia in the era of COVID-19

COVID-19 and impact on gynecologic oncology practice in India: Results of a nationwide survey

The future of PARP inhibitors in prostate cancer

Managing acute myeloid leukaemia during the COVID-19 pandemic

Meet the Expert: Daniel Seymour

Gut microbiome disturbance by antibiotic treatment early in life is sufficient to induce leukaemia in predisposed mice

COMBI-AD trial: Adjuvant dabrafenib plus trametinib in patients with resected stage III BRAF V600–mutant melanoma

Safety and efficacy of CD19/CD22 CAR T cells in children and young adults with relapsed/refractory ALL

Medical oncology care amidst the COVID-19 pandemic at the National University Hospital in the Philippines

IMvigor130: Atezolizumab with or without chemotherapy in metastatic urothelial cancer

Checkmate 9LA: Nivolumab, ipilimumab and chemotherapy for stage IV NSCLC